Document Detail

Minimizing Nuclear Medicine Technologist Radiation Exposure during 131I-MIBG Therapy.
MedLine Citation:
PMID:  23287519     Owner:  NLM     Status:  In-Data-Review    
ABSTRACT: I-metaiodobenzylguanidine is a norepinephrine analog that concentrates in adrenergic tissue and has been shown to be an effective radiotherapeutic agent used to treat tumors of neural crest origin, particularly neuroblastoma, a sympathetic nervous system malignancy of children. The purpose of this study was to determine the radiation dose received by nuclear medicine technologists while preparing and administering I-metaiodobenzylguanidine therapy dosages, and if any changes could be implemented that would reduce a technologist's dose. The study involves the collection of total whole body doses received by technologists during the treatment of six patients. Patient dosages ranged from 9.25 to 31.1 GBq, with radiation exposures to the nuclear medicine technologists averaging 0.024 μSv per MBq administered to the patient. Subsequently, the doses received by the technologists were analyzed with respect to specific process steps performed during I-metaiodobenzylguanidine therapy including package receipt, dosage preparation, and dosage administration. Results show that the largest contribution to the technologist's whole body radiation dose (>83%) is received during the dosage administration process step. After additional shielding was installed for use during the dosage administration process step, technologists' doses decreased 80%.
Brian K Turpin; Victoria R Morris; Lisa Lemen; Brian D Weiss; Michael J Gelfand
Related Documents :
23205809 - Dose-volume effects on brainstem dose tolerance in radiosurgery.
18192689 - Modulation of aflatoxin biomarkers in human blood and urine by green tea polyphenols in...
17981079 - Study on potential effects of "902-mhz gsm-type wireless communication signals" on dmba...
23039659 - A method of dose reconstruction for moving targets compatible with dynamic treatments.
24682029 - Prediction of clinical irrelevance of pk differences in atorvastatin using pk/pd models...
23813109 - High-dose (2.0 mg) intravitreal ranibizumab for recalcitrant radiation retinopathy.
25024259 - Phase i dose escalation study of medi-573, a bispecific, anti-ligand monoclonal antibod...
20576419 - Beneficial effect of inhaled mannitol and cough in asthmatics with mucociliary dysfunct...
2222949 - Effect of captopril on renal function in hypertensive dogs with unilateral renal artery...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Health physics     Volume:  104     ISSN:  1538-5159     ISO Abbreviation:  Health Phys     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-04     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  2985093R     Medline TA:  Health Phys     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S43-6     Citation Subset:  IM    
*University of Cincinnati, Cincinnati, OH.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Laser safety program at woods hole oceanographic institution.
Next Document:  Methodology for a bounding estimate of activation source-term.